Abstract
Bezlotoxumab (Zinplava™) is a human monoclonal antibody against Clostridium difficile toxin B developed by Merck & Co. In October 2016 it was approved in the USA for reducing the recurrence of C. difficile infection. This article summarizes the milestones in the development of bezlotoxumab leading to this first approval for use in patients receiving antibacterial drug treatment for C. difficile infection who are at high risk for recurrence of C. difficile infection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83(2):822–31.
US Food and Drug Administration. FDA briefing document: bezlotoxumab injection. 2016. http://www.fda.gov/. Accessed 26 Oct 2016.
Merck & Co. FDA approves Mercks ZINPLAVATM (bezlotoxumab) to reduce recurrence of Clostridium difficile infection (CDI) in adult patients receiving antibacterial drug treatment for CDI who are at high risk of CDI recurrence [media release]. 21 Oct 2016.
Merck & Co. Merck announces FDA acceptance of biologics license application for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile infection recurrence [media release]. 27 Jan 2016. http://www.merck.com.
Merck & Co Inc, Medarex Inc, Massachusetts Biologic Laboratories. Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories sign exclusive licensing agreement for investigational monoclonal antibody combination for Clostridium difficile infection [media release]. 21 Apr 2009.
Orth P, Xiao L, Hernandez LD, et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014;289(26):18008–21.
Hernandez LD, Racine F, Xiao L, et al. Broad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modeling. Antimicrob Agents Chemother. 2015;59(2):1052–60.
Koon HW, Shih DQ, Hing TC, et al. Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrob Agents Chemother. 2013;57(7):3214–23.
Warn P, Thommes P, Sattar A, et al. Disease progression and resolution in rodent models of Clostridium difficile infection and impact of antitoxin antibodies and vancomycin. Antimicrob Agents Chemother. 2016;. doi:10.1128/aac.00974-16.
Merck Sharp & Dohme Corp. Zinplava™ (bezlotoxumab): US prescribing information. 2016. http://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf. Accessed 25 Nov 2016.
Dubberke ER, Gerding D, Kelly CP, et al. Efficacy of bezlotoxumab in patients receiving metronidazole, vancomycin, or fidaxomicin for treatment of Clostridium difficile infection (CDI) [abstract no. 838]. In: IDWeek. 2016.
Wilcox M, Gerding D, Poxton I, et al. Phase 3 double-blind study of actoxumab (ACT) bezlotoxumab (BEZ) for prevention of recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics (MODIFY I). In: Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy. 2015.
Gerding D, Wilcox M, Poxton I, et al. Phase 3 double-blind study of bezlotoxumab (BEZ) alone with actoxumab (ACT) for prevention of recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics (MODIFY II). In: Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy. 2015.
Goldstein E, Citron D, Gerding D, et al. Recurrent Clostridium difficile infection (rCDI) and colonization in the 12 months following administration of bezlotoxumab (BEZ) alone and in combination with actoxumab (ACT). In: ASM Microbe. 2016.
Gerding DN, Kelly CP, Rahav G, et al. Efficacy of bezlotoxumab, the monoclonal antibody targeting C. difficile toxin B, for prevention of C. difficile infection (CDI) recurrence in patients at high risk of recurrence or CDI-related adverse outcomes [abstract no. 2000]. In: 26th European Congress of Clinical Microbiology and Infectious Diseases. 2016.
Johnson S, Sambol S, Best E, et al. Efficacy of bezlotoxumab in patients infected with strains of Clostridium difficile associated with poor outcomes [abstract no. 2114]. In: IDWeek. 2016.
Basu A, Prabhu VS, Marcella S, et al. Bezlotoxumab is associated with a reduction in cumulative hospitalized days: analysis of the hospitalization data from the MODIFY I and II clinical trials [abstract no. 2E-2]. In: 16th Biennial European Conference. 2016.
Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197–205.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham is a contracted employee of Adis, Springer SBM.
Author information
Authors and Affiliations
Corresponding author
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Markham, A. Bezlotoxumab: First Global Approval. Drugs 76, 1793–1798 (2016). https://doi.org/10.1007/s40265-016-0673-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-016-0673-1